These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 20060832)

  • 1. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
    Rauch A; Kutalik Z; Descombes P; Cai T; Di Iulio J; Mueller T; Bochud M; Battegay M; Bernasconi E; Borovicka J; Colombo S; Cerny A; Dufour JF; Furrer H; Günthard HF; Heim M; Hirschel B; Malinverni R; Moradpour D; Müllhaupt B; Witteck A; Beckmann JS; Berg T; Bergmann S; Negro F; Telenti A; Bochud PY; ;
    Gastroenterology; 2010 Apr; 138(4):1338-45, 1345.e1-7. PubMed ID: 20060832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
    Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
    Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IL28B for chronic hepatitis C treatment toward personalized medicine.
    Matsuura K; Watanabe T; Tanaka Y
    J Gastroenterol Hepatol; 2014 Feb; 29(2):241-9. PubMed ID: 24325405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
    Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J
    Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
    Sakamoto N; Nakagawa M; Tanaka Y; Sekine-Osajima Y; Ueyama M; Kurosaki M; Nishida N; Tamori A; Yuki NS; Itsui Y; Azuma S; Kakinuma S; Hige S; Itoh Y; Tanaka E; Hiasa Y; Izumi N; Tokunaga K; Mizokami M; Watanabe M;
    J Med Virol; 2011 May; 83(5):871-8. PubMed ID: 21360545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.
    Barreiro P; Pineda JA; Rallón N; Naggie S; Martín-Carbonero L; Neukam K; Rivero A; Benito JM; Caruz A; Vispo E; Camacho A; Medrano J; McHutchison J; Soriano V
    J Infect Dis; 2011 Jun; 203(11):1629-36. PubMed ID: 21592993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
    Lange CM; Moradpour D; Doehring A; Lehr HA; Müllhaupt B; Bibert S; Bochud PY; Antonino AT; Pascual M; Farnik H; Shi Y; Bechstein WO; Moench C; Hansmann ML; Sarrazin C; Lötsch J; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Aug; 55(2):322-7. PubMed ID: 21147186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
    J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection.
    Laird ME; Mohsen A; Duffy D; Mamdouh R; LeFouler L; Casrouge A; El-Daly M; Rafik M; Abdel-Hamid M; Soulier A; Pawlotsky JM; Hézode C; Rosa I; Renard P; Mohamed MK; Bonnard P; Izopet J; Mallet V; Pol S; Albert ML; Fontanet A
    J Hepatol; 2014 Oct; 61(4):770-6. PubMed ID: 24905490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
    Fernández-Rodríguez A; Rallón N; Berenguer J; Jiménez-Sousa MA; Cosín J; Guzmán-Fulgencio M; Restrepo C; Lopez JC; García-Álvarez M; Miralles P; Soriano V; Benito JM; Resino S
    AIDS; 2013 Jan; 27(2):163-73. PubMed ID: 23135173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
    Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
    J Viral Hepat; 2013 Jan; 20(1):59-64. PubMed ID: 23231085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
    Bochud PY; Bibert S; Negro F; Haagmans B; Soulier A; Ferrari C; Missale G; Zeuzem S; Pawlotsky JM; Schalm S; Hellstrand K; Neumann AU; Lagging M
    J Hepatol; 2011 Nov; 55(5):980-8. PubMed ID: 21354446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.
    Cavalcante LN; Abe-Sandes K; Angelo AL; Machado TM; Lemaire DC; Mendes CM; Pinho JR; Malta F; Lyra LG; Lyra AC
    Liver Int; 2012 Mar; 32(3):476-86. PubMed ID: 22098416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.